Vistagen, which is developing two pherine-based nasal sprays licensed from Pherin Pharmaceuticals (PH10 and PH94B), announced that it has reached an agreement to acquire Pherin and its entire pipeline. According to Vistagen, the deal includes ~12.4 million shares of the company's common stock as well as "a nominal amount of cash." PH10 was recently granted Fast … [Read more...] about Vistagen announces agreement to acquire Pherin Pharmaceuticals
Business
Third Pole gets $32 million to support development of eNOcare inhaled nitric oxide device
Inhaled nitric oxide (iNO) delivery device developer Third Pole Therapeutics announced that it has received a $32 million equity investment "from a large medical device innovator." In February 2022, the company announced the closing of a $25 million financing. Chiesi acquired global rights to develop and commercialize Third Pole's tankless iNO technology in April … [Read more...] about Third Pole gets $32 million to support development of eNOcare inhaled nitric oxide device
CF Foundation invests $4.85 million in Aridis Pharmaceuticals to support development of AR-501 inhaled gallium
According to Aridis Pharmaceuticals, the Cystic Fibrosis Foundation has made a $4.85 million investment in Aridis common stock to support continued development of AR-501 nebulized gallium citrate for the treatment of chronic lung infections in CF patients, bringing the CF Foundation's total funding for the project to $12.5 million. AR-501 has been granted orphan, … [Read more...] about CF Foundation invests $4.85 million in Aridis Pharmaceuticals to support development of AR-501 inhaled gallium
Evoke gets new US patent covering Gimoti metoclopramide nasal spray
According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a new patent covering Evoke's Gimoti metoclopramide nasal spray. The new patent (No. 11,517,545), which expires in 2038, is titled "Treatment of Moderate and Severe Gastroparesis." The FDA approved Gimoti for the treatment of diabetic gastroparesis in June 2020 and granted 3 … [Read more...] about Evoke gets new US patent covering Gimoti metoclopramide nasal spray
Pulmocide raises $52 million for further development of inhaled opelconazole
Pulmocide announced that it has closed a $52 million a Series C extension round, with the proceeds to be used for continued development of its PC945 inhaled opelconazole for the treatment of invasive pulmonary Aspergillosis (IPA). Opelconazole has been granted orphan drug, Fast Track, and Qualified Infectious Disease Product designations. In December 2021, … [Read more...] about Pulmocide raises $52 million for further development of inhaled opelconazole
Vistagen announces planned Phase 1 trial of new formulation of PH10 nasal spray
After receiving a "Study May Proceed" letter from the FDA, Vistagen has announced plans for a Phase 1 trial of a re-formulated version of PH10 pherin nasal spray. The new Phase 1 study is expected to begin in early 2023 as part of plans to develop the nasal spray for the treatment of major depressive disorder. A previous Phase 2a trial of PH10 for that indication … [Read more...] about Vistagen announces planned Phase 1 trial of new formulation of PH10 nasal spray
Nuance Pharma takes steps towards marketing Bentrio nasal spray in Hong Kong and Macau
Nuance Pharma has announced a deal with DKSH Business Unit Healthcare for commercialization of Bentrio, an API-free, bentonite-based OTC nasal spray for protection against allergens and viruses, in Hong Kong and Macau. Bentrio is currently marketed in several countries in Europe for allergic rhinitis, and in the US, the nasal spray received 510(k) clearance in June … [Read more...] about Nuance Pharma takes steps towards marketing Bentrio nasal spray in Hong Kong and Macau
Hyloris announces plans to develop an intranasal TRPV1 agonist for the treatment of idiopathic rhinitis
Belgium-based Hyloris Pharmaceuticals announced that it has added an intranasal TRPV1 agonist (HY-083) for the treatment of idiopathic rhinitis to its pipeline. TRPV1 (transient receptor potential cation channel subfamily V member 1) is overexpressed in the nasal mucosa in idiopathic rhinitis. According to the company, "Hyloris’ treatment approach is to activate and … [Read more...] about Hyloris announces plans to develop an intranasal TRPV1 agonist for the treatment of idiopathic rhinitis
Kindeva Drug Delivery to merge with Meridian Medical Technologies
CDMO Kindeva Drug Delivery, which specializes in inhalation, intradermal, and transdermal drug delivery, has announced that it will merge with fellow Altaris Capital Partners company Meridian Medical Technologies, which specializes in autoinjectors. Altaris acquired Kindeva (formerly 3M Drug Delivery Systems) from 3M in 2020 and acquired Meridian from Pfizer in 2021. … [Read more...] about Kindeva Drug Delivery to merge with Meridian Medical Technologies
Relief Therapeutics gets exclusive rights to aviptadil in settlement with NRx Pharmaceuticals
Relief Therapeutics and NRx Pharmaceuticals (formerly NeuroRx) said that they have settled litigation that originated with a dispute over payment for a clinical trial of nebulized aviptadil (RLF-100) for the treatment of COVID-19. According to the companies, Relief will take possession of all NRx assets related to aviptadil, "including its regulatory filings, patent … [Read more...] about Relief Therapeutics gets exclusive rights to aviptadil in settlement with NRx Pharmaceuticals